Metabolic Analysis and Renal Protective Effects of Linagliptin and Empagliflozin in Alport Syndrome

Overview of attention for article published in Kidney360, May 2024

Altmetric Badge

About this Attention Score

Above-average Attention Score compared to outputs of the same age (62nd percentile)
Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter: 5 X users

Readers on

mendeley: 7 Mendeley

So far, Altmetric has seen 6 X posts from 5 X users, with an upper bound of 30,076 followers.

Metabolic Analysis and Renal Protective Effects of Linagliptin and Empagliflozin in #Alport Syndrome https://t.co/V3o3yaou4P https://t.co/G2PTcFpgC1

RT @ASNKidney360: Though Alport syndrome (AS) is known as a non-metabolic CKD, studies have shown disruptions in lipid metabolism in AS. Th…

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 2 additional X posts.